Status
Conditions
Treatments
About
Since initial reports of a novel coronavirus emerged from Hubei province, China, the world has been engulfed by a pandemic with over 3 million cases and 225,000 deaths by 30th April 2020. Health care systems around the world have struggled to cope with the number of patients presenting with COVID-19 (the disease caused by the SARS-CoV-2 virus). Although the majority of people infected with the virus have a mild disease, around 20% experience a more severe illness leading to hospital admission and sometimes require treatment in intensive care. People that survive severe COVID-19 are likely to have persistent health problems that would benefit from rehabilitation.
Pulmonary rehabilitation (PR) is a multidisciplinary program which is designed to improve physical and social performance and is typically provided for people with chronic lung conditions. PR courses typically last 6-12 weeks with patients attending classes once or twice weekly and consist of exercise and education components. PR is known to improve symptoms (e.g. breathlessness), quality of life and ability to exercise in those with lung conditions. Breathlessness is a very common symptom reported by people presenting to hospital with COVID-19 and loss of physical fitness will be very common. Using existing pulmonary rehabilitation programmes as a model, we have developed a tele-rehabilitation programme (a programme that will be delivered using video link to overcome the challenges faced by social distancing and shielding advice) for people that have been critically ill with COVID-19. In order to prove whether people benefit from this tele-rehabilitation programme after being admitted to hospital following COVID-19 we would need to perform a large clinical trial. However, before doing this it is important for us to answer some key questions:
Full description
STUDY AIMS AND OBJECTIVES Aim: To address the uncertainties relating to the design and conduct of a tele-rehabilitation programme and substantive phase 3 randomised controlled trial to evaluate its effectiveness for people that have been hospitalised with COVID-19 and required additional respiratory support (non-invasive and / or invasive ventilation).
Objectives: Specific study objectives will address uncertainties in four areas.
In addition to the above feasibility study objectives changes in symptoms, quality of life and measures of functional capacity over time to provide preliminary insights into the natural history of recovery post COVID-19 and potential effect of tele-rehabilitation will be explored.
. STUDY DESIGN Single centre, fast-track (wait-list), randomised controlled feasibility trial of tele-rehabilitation for patients that have been hospitalised with COVID-19 and required non-invasive and/or invasive mechanical ventilation. Patients will be randomised 1:1 to fast-track or wait-list groups using random permuted blocks.
SUMMARY The tele-rehabilitation programme will be delivered by trained therapists and will be structured using conventional pulmonary rehabilitation principles.
Participants will be randomised to fast-track or wait-list groups. All participants will receive the intervention during the course of the trial. Participants randomised to the fast-track group will receive the intervention 14 ± 7 days after randomisation. Participants randomised to the wait-list group will receive the intervention 56 ± 7 days after randomisation.
TELE-REHABILITATION INTERVENTION The tele-rehabilitation programme will be delivered via an NHSX / NHS Digital approved commercial video conferencing application. It will comprise an initial assessment followed by 12 classes delivered by video link over a 6 week period. Participants will be advised to undertake exercises on 5 days each week Participants will be contacted by the interventional physiotherapists prior to commencing the intervention and undertake a virtual (telephone or video) consultation to check eligibility, accessibility and safety to exercise with remote supervision. At this consultation they will be provided with the exercise programme based on their current level of exercise tolerance and functional activity level. Twice a week they will be invited to join a virtual exercise and education group during which the therapists can observe the participants undertaking the exercises. This will allow for safety checks, progression or modifications to be made to the exercises by the therapists. Participants will be taken through a warm up and cool down plus exercise, after which they will be invited to stay to receive educational advice on relevant topics such as managing breathlessness; managing fatigue; diet and hydration; the importance of exercise; returning to the workplace etc. Participants will also be allowed time to share experiences with each other to engender a sense of community and peer support.
ARRANGING THE INTERVENTION Site staff will be trained in local procedures for referral for the intervention. Referral will be undertaken immediately following randomisation and participants informed of their group allocation and start date of the intervention.
Intervention Fidelity Training in the tele-rehabilitation programme will be provided for the therapists involved in intervention delivery. The tele-rehabilitation being delivered has been developed locally as the standard clinical care. For the purpose of the trial, training will be delivered by local therapist familiar with the intervention. A record of staff training in the intervention should be retained in the site file and only those that have received training should be involved in intervention delivery.
Delivery of the intervention should be documented by the delivering therapist within the participant's medical record and CRF. If any components of the intervention are not delivered then the reason for this must be documented in the participant's medical record and CRF.
OUTCOMES AND MEASURES This is a feasibility trial and therefore the primary outcome measures address areas of uncertainty relating to design and delivery of tele-rehabilitation and a Phase 3 randomised controlled trial. These outcomes are termed feasibility outcomes. As part of this trial a number of clinical outcomes will be evaluated with the aim of identifying the most appropriate primary outcome for a subsequent trial and evaluating acceptability and suitability of these measures.
Feasibility Outcomes
The following feasibility outcomes will be assessed:
Clinical outcomes will be measured and data synthesized to inform the sample size of a definitive trial.
The traffic light system will be used for feasibility outcomes Clinical Outcomes
Symptoms
Quality of Life The EQ-5D-5L and the EQ visual analogue scale (EQ VAS) will be used to measure participants quality of life. The EQ-5D-5L measures 5 dimensions of health state (mobility, self-care, usual activities, pan/discomfort and anxiety/depression) using 5 levels (no problem, slight problem, moderate problems, severe problems, extreme problems). The EQ VAS asks patients to self-rate their health on a vertical VAS from 'the best health you can imagine' to 'the worst health you can imagine'[10].
Mood The hospital anxiety and depression scale (HADS) [11]. The HADS is a short well validated screening assessment tool which will not add unnecessarily to a participant's burden.
The EQ-5D-5L anxiety and depression domain will also provide insight into participants' mood.
Exercise Capacity
The One-Minute Sit-to-Stand Test (STST) assesses the number of times a participant can transition between the sitting and standing positions in a 1 minute period. The STST has shown good correlation with other well validated measures of functional capacity in people with chronic respiratory disease [12] and is suitable for an elderly population [13]. Participants will undertake this assessment in their own homes while observed over a video link. The requirement for specific equipment and space precludes the use of other measures of functional capacity (for example, the 6-minute walk test or incremental shuttle walk test). Other than a chair, the STST requires no specialised equipment and therefore can be undertaken by participants in their own homes.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Significant comorbid physical or mental illness considered by the investigator to:
40 participants in 2 patient groups
Loading...
Central trial contact
Michael Crooks, MRCP/MD; Angela Green, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal